Professor of Neurology at the Vanderbilt University Medical Center in the US, Dr Daniel Claassen, was principal investigator of the Alterity Therapeutics' (ASX:ATH) biomarkers of progression in ...
A leading neurologist involved in the clinical development of Alterity’s lead compound ATH434 believes it could have a hugely positive impact for sufferers of MSA. Professor of Neurology at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results